Highlights
- Ruxolitinib 1.5% cream significantly reduced the count of abscesses and inflammatory nodules (AN) at 16 weeks compared to vehicle in patients with mild-to-moderate HS.
- The treatment was well tolerated with no reported Grade 3 or higher treatment-emergent adverse events, offering a safer alternative to long-term systemic antibiotics.
- Sustained clinical benefits were observed through week 32 with an “as-needed” application regimen, suggesting a potential for maintenance therapy.
- This study marks a pivotal shift toward targeted topical therapies for earlier-stage HS (Hurley I/II), where approved options are currently non-existent.
Background
Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease characterized by recurrent, painful nodules, abscesses, and draining tunnels in intertriginous areas. While the therapeutic landscape for moderate-to-severe HS has expanded with the approval of biologics targeting tumor necrosis factor (TNF) and interleukin (IL)-17, patients with milder forms of the disease (Hurley stage I and early II) have been largely overlooked in clinical drug development.
Current management for mild-to-moderate HS relies heavily on off-label use of topical and systemic antibiotics, which carry risks of microbiome disruption and antimicrobial resistance. The pathogenesis of HS involves a complex interplay of hair follicle occlusion and a hyper-inflammatory immune response mediated by the JAK/STAT signaling pathway. Ruxolitinib, a potent Janus kinase (JAK) 1 and JAK 2 inhibitor, has shown efficacy in other dermatologic conditions like atopic dermatitis and vitiligo. This Phase 2 study evaluates whether topical ruxolitinib can address the significant unmet need for effective, targeted therapy in patients with localized, non-tunneled HS.
Key Content
Study Design and Patient Demographics
The Phase 2 randomized, double-blind, vehicle-controlled trial (Porter et al., 2026) enrolled 69 adults diagnosed with Hurley stage I or II HS. Inclusion criteria specified an abscess and inflammatory nodule (AN) count of 3 to 10, specifically excluding patients with draining tunnels to focus on the “milder” spectrum of the disease.
Patients were randomized 1:1 to apply either 1.5% ruxolitinib cream or a vehicle cream twice daily for a 16-week double-blind period. Following this, an open-label extension allowed all patients to use the 1.5% ruxolitinib cream on an as-needed basis through week 32. The primary efficacy endpoint was the change from baseline in the total AN count at week 16.
Efficacy Outcomes: Primary and Secondary Endpoints
At the primary endpoint (Week 16), the ruxolitinib group showed a statistically significant reduction in inflammatory burden compared to the vehicle group:
- AN Count Reduction: The least squares (LS) mean change from baseline was -3.61 for the ruxolitinib group versus -2.42 for the vehicle group (P = .0215).
- Flare Prevention: Patients utilizing ruxolitinib cream experienced fewer disease flares during the initial 16 weeks compared to those on the vehicle.
- Maintenance of Response: In the as-needed phase (Weeks 17–32), the improvement achieved by the ruxolitinib-treated group was sustained, and those who switched from vehicle to ruxolitinib also demonstrated a reduction in AN counts.
Safety and Tolerability Profile
The safety data were highly encouraging for a topical application. Most reported treatment-emergent adverse events (TEAEs) were mild to moderate in severity. Crucially, no Grade ≥3 TEAEs occurred. The local tolerability was high, with minimal reports of application-site reactions, which is a significant factor in ensuring patient adherence for a chronic condition like HS.
Mechanism and Translational Context
The efficacy of ruxolitinib in HS underscores the importance of the JAK/STAT pathway in the disease’s follicular and perifollicular inflammation. By inhibiting JAK1 and JAK2, ruxolitinib modulates the signaling of several key pro-inflammatory cytokines, including interferon-gamma and IL-6, which are known to be elevated in HS lesions. This study provides clinical validation that localized, topical inhibition can be sufficient to suppress the inflammatory cascade in early-stage disease without the systemic risks associated with oral JAK inhibitors (e.g., thromboembolism or cytopenias).
Expert Commentary
The results from Porter et al. represent a significant milestone in HS research. For years, clinicians have struggled to manage Hurley Stage I patients who are too symptomatic for simple topical washes but not yet severe enough for systemic biologics.
Methodological Strengths and Limitations:
The randomized, double-blind design provides high-quality evidence. However, the relatively small sample size (n=69) and the imbalance in race and discontinuation rates between groups warrant caution. HS disproportionately affects patients of color, and the generalizability of these results across all phototypes remains an area for further investigation in Phase 3 trials.
Comparison with Other Neutrophilic Dermatoses:
Interestingly, the push for standardized outcome measures in related neutrophilic conditions—such as the international eDelphi consensus for Pyoderma Gangrenosum (PMID: 41784109)—highlights a broader movement toward rigorous, evidence-based dermatology. Just as a minimum data set is being established for PG to improve registry data, the use of AN counts in this ruxolitinib study emphasizes the need for objective, reproducible metrics in HS clinical trials.
Clinical Applicability:
If approved, ruxolitinib cream could become the first-line targeted therapy for patients with 3-10 inflammatory nodules. It potentially offers a “proactive” rather than “reactive” management strategy, possibly preventing the progression from Hurley Stage I to the irreversible scarring and tunneling characteristic of Stage III.
Conclusion
Ruxolitinib 1.5% cream has demonstrated a superior clinical benefit compared to vehicle in reducing the primary inflammatory lesions of mild-to-moderate HS. Its favorable safety profile through 32 weeks of use makes it a promising candidate for the treatment of a patient population currently underserved by the medical community. Future research should focus on larger, more diverse cohorts and explore the long-term potential of topical JAK inhibition to modify the natural history of HS progression.
References
- Porter ML, Ferreira-Cornwell MC, Wang M, Nawaz H, Gooderham MJ. Efficacy and safety of ruxolitinib cream in patients with mild to moderate hidradenitis suppurativa: Results from a randomized, double-blind, vehicle-controlled phase 2 study. J Am Acad Dermatol. 2026 Mar;94(3):879-887. PMID: 41248765.
- Orfali RL, et al. Minimum Data Set for Treatment Effectiveness in Pyoderma Gangrenosum for an International Registry: An International Multidisciplinary eDelphi Consensus. Br J Dermatol. 2026. PMID: 41784109.
